Transdermal scopolamine for reduction of drooling in developmentally delayed children

Dev Med Child Neurol. 1994 Jun;36(6):484-6. doi: 10.1111/j.1469-8749.1994.tb11877.x.


Ten developmentally delayed children with excessive drooling were randomized in a double-blind, placebo-controlled study to assess the efficacy and safety of transdermal scopolamine. Over half of the patients had a statistically significant reduction in drooling, and one-third had cessation of drooling, while wearing the scopolamine patch. This short-term study supports earlier reports of the safety and efficacy of transdermal scopolamine for reducing excessive drooling in developmentally disabled children.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Administration, Cutaneous
  • Adolescent
  • Child
  • Developmental Disabilities / complications*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Placebos
  • Scopolamine / therapeutic use*
  • Sialorrhea / drug therapy*
  • Sialorrhea / etiology


  • Placebos
  • Scopolamine